Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study

BACKGROUND: The relative lack of specifically targeted agents for HER2-negative metastatic breast cancer (MBC) makes the need for new agents or combination therapies to maximize clinical benefit while reducing toxicity critical. OBJECTIVES: To retrospectively analyze the efficacy and safety of eribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mingxia, Shao, Bin, Wan, Donggui, Liu, Jiaxuan, He, Maiyue, Chai, Yue, Sang, Die, Wang, Jiayu, Ma, Fei, Fan, Ying, Yuan, Peng, Xu, Binghe, Li, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571693/
https://www.ncbi.nlm.nih.gov/pubmed/37841751
http://dx.doi.org/10.1177/17588359231204856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571693/
https://www.ncbi.nlm.nih.gov/pubmed/37841751
http://dx.doi.org/10.1177/17588359231204856

Ejemplares similares